Precision Oncology: Emerging Technologies & Implementation
Jan 12–15, 2025 | Beaver Run Conference Center, Breckenridge, CO, United States
Scientific Organizers:
John D. Carpten, David Solit and Chanita Hughes-Halbert
In Person
On Demand
Jan 12–15, 2025 | Beaver Run Conference Center, Breckenridge, CO, United States
Scientific Organizers:
John D. Carpten, David Solit and Chanita Hughes-Halbert
Available Formats:
In Person
On Demand
Supported by Bristol-Myers Squibb Company
Available Formats: = In Person = On Demand
Merchandise Options
Registration Options
Sunday, January 12, 2025
Booking Function
Registration
4:00–8:00 PM
Colorado Ballroom Foyer
Welcome Mixer
6:00–8:00 PM
Colorado Ballroom Foyer
Monday, January 13, 2025
Breakfast
7:00–8:00 AM
Summit Gallery
Welcome and Keynote Address
8:00–9:00 AM
Peaks 4 & 5
Elaine R Mardis, Nationwide Children's Hospital
Complex Molecular Characterization of Pediatric Cancers: Setting the Stage for Precision Diagnosis and Therapy
Complex Molecular Characterization of Pediatric Cancers: Setting the Stage for Precision Diagnosis and Therapy
Targeted Therapeutics
9:00–11:15 AM
Peaks 4 & 5
Frank McCormick, University of California, San Francisco
Targeting Ras in Human Cancer
Targeting Ras in Human Cancer
Christine Lovly, Vanderbilt University
Sensitivity and Resistance to Kinase Inhibitors in Cancer
Sensitivity and Resistance to Kinase Inhibitors in Cancer
Lillian L Siu, Princess Margaret Cancer Centre
Targeted Cytotoxics: Advances in Antibody Drug Conjugates
Targeted Cytotoxics: Advances in Antibody Drug Conjugates
Hee Won Yang, Columbia University
Short Talk: Deciphering the Mechanism Underlying Resistance to pan-RAS Inhibitors
Short Talk: Deciphering the Mechanism Underlying Resistance to pan-RAS Inhibitors
Jeff Perry, City of Hope
Short Talk: Small Molecule-Based Targeting of PCNA Protein to Develop a Cancer-Selective Chemotherapy
Short Talk: Small Molecule-Based Targeting of PCNA Protein to Develop a Cancer-Selective Chemotherapy
Coffee Break
9:30–9:50 AM
Colorado Ballroom Foyer
Poster Setup
11:15–1:00 PM
Peaks 1 - 3
On Own for Lunch
11:15–2:30 PM
Poster Viewing
1:00–10:00 PM
Peaks 1 - 3
Panel Discussion: FDA
2:30–4:30 PM
Peaks 4 & 5
Coffee Available
4:30–5:00 PM
Colorado Ballroom Foyer
Clinical Trial Advances/Insights/Design
5:00–7:00 PM
Peaks 4 & 5
David Solit, Memorial Sloan Kettering Cancer Center
Lessons from the Study of Exceptional Responders
Lessons from the Study of Exceptional Responders
Vivek Subbiah, Sarah Cannon Research Institute
New Clinical Trial Designs for the Precision Medicine Era
New Clinical Trial Designs for the Precision Medicine Era
Patricia LoRusso, Yale School of Medicine
Expanding Clinical Research Innovations into the Community
Expanding Clinical Research Innovations into the Community
Daniel Richard Gomez †, Memorial Sloan Kettering Cancer Center
Short Talk: Circulating Tumor DNA as a Biomarker in De Novo Oligometastatic Lung Cancer
Short Talk: Circulating Tumor DNA as a Biomarker in De Novo Oligometastatic Lung Cancer
Sunantha Sethuraman, Repare Therapeutics
Short Talk: Utility of Circulating Tumor DNA (Ctdna) to Support Early Clinical Development of the PKMYT1 Inhibitor Lunresertib (Lunre) Alone or in Combination with the ATR Inhibitor Camonsertib (Cam) in the MYTHIC Phase I Trial
Short Talk: Utility of Circulating Tumor DNA (Ctdna) to Support Early Clinical Development of the PKMYT1 Inhibitor Lunresertib (Lunre) Alone or in Combination with the ATR Inhibitor Camonsertib (Cam) in the MYTHIC Phase I Trial
Social Hour with Lite Bites
7:00–8:00 PM
Peaks 1 - 3
Poster Session 1
7:30–10:00 PM
Peaks 1 - 3
Tuesday, January 14, 2025
Breakfast
7:00–8:00 AM
Peaks 1 - 3
Precision Oncology and Disparities (Implementation and Discovery)
8:00–11:00 AM
Peaks 4 & 5
Rick Kittles, Morehouse School of Medicine
Ancestry Informative Markers and Cancer Risk and Outcomes
Ancestry Informative Markers and Cancer Risk and Outcomes
Clayton C. Yates, Johns Hopkins School of Medicine
Using Precision Oncology to Support Innovation in Prostate Cancer Equity
Using Precision Oncology to Support Innovation in Prostate Cancer Equity
Chanita Hughes-Halbert, University of Southern California
Intersection between Social and Biological Risk Factors on the Pathway to Cancer Health Equity
Intersection between Social and Biological Risk Factors on the Pathway to Cancer Health Equity
Rizwana Mia, South African Medical Research Council
Precision Oncology disparities in South Africa
Precision Oncology disparities in South Africa
Nick Pannunzio †, University of Califormia Irvine
Short Talk: Increased AID Results in Mutations at the CRLF2 Locus Implicated in Latin American ALL Health Disparities
Short Talk: Increased AID Results in Mutations at the CRLF2 Locus Implicated in Latin American ALL Health Disparities
Coffee Break
9:00–9:20 AM
Colorado Ballroom Foyer
Poster Setup
11:00–1:00 PM
Peaks 1 - 3
On Own for Lunch
11:00–1:30 PM
Poster Viewing
1:00–10:00 PM
Peaks 1 - 3
Symposia Spotlight: Late-Breaking research presentations selected from abstract submissions
1:30–3:15 PM
Peaks 4 & 5
Tomas Babak †, Leapfrog Bio
EP300 loss of function is a pan-cancer sensitizer to BET inhibition
EP300 loss of function is a pan-cancer sensitizer to BET inhibition
Matthew Eason †, University of Maryland School of Medicine
Select Pleckstrin Homology Domains Regulate PI3K/Akt Through the P85 Inhibitor and Dissemination Suppressor (PIDS) Motif to Block Breast Cancer Dissemination
Select Pleckstrin Homology Domains Regulate PI3K/Akt Through the P85 Inhibitor and Dissemination Suppressor (PIDS) Motif to Block Breast Cancer Dissemination
Yaniv Kazansky †, Weill Cornell Medicine
Overcoming Clinical Resistance to EZH2 Inhibition Using Rational Epigenetic Combination Therapy
Overcoming Clinical Resistance to EZH2 Inhibition Using Rational Epigenetic Combination Therapy
Luke Pike, Memorial Sloan Kettering Cancer Center
EGFR Alteration Subtype Predicts the Benefit Of Stereotactic Radiosurgery in Patients with NSCLC Brain Metastasis
EGFR Alteration Subtype Predicts the Benefit Of Stereotactic Radiosurgery in Patients with NSCLC Brain Metastasis
Poulikos I. Poulikakos †, Icahn School of Medicine at Mount Sinai
RAF/MEK Glue Mechanism on RAF Enables RAS Mutant Tumor-Selective Therapy
RAF/MEK Glue Mechanism on RAF Enables RAS Mutant Tumor-Selective Therapy
Hannah C Watkins †, Adimab
Development of Anti-CD3 Heavy Chain-Only Antibodies for Use in T Cell Engaging Therapeutics
Development of Anti-CD3 Heavy Chain-Only Antibodies for Use in T Cell Engaging Therapeutics
Career Roundtable
3:30–4:30 PM
Peaks 4 & 5
Coffee Available
4:30–5:00 PM
Colorado Ballroom Foyer
Precision Immuno-oncology / Overcoming Immune Evasion Through Combination Therapies
5:00–7:00 PM
Peaks 4 & 5
Padmanee Sharma, University of Texas MD Anderson Cancer Center
Advancing Immune Checkpoint Targets in Cancer
Advancing Immune Checkpoint Targets in Cancer
Marta Luksza, Icahn School of Medicine at Mount Sinai
Novel Computational Methods to Define Immunotherapy Sensitivity
Novel Computational Methods to Define Immunotherapy Sensitivity
Alona Sosinsky, Genomics England
Integrating Genome Sequencing into Clinical Practice for Cancer Patients
Integrating Genome Sequencing into Clinical Practice for Cancer Patients
Christine Yeh †, Stanford University
Short Talk: Mapping Spatial Organization and Genetic Cell-State Regulators to Target Immune Evasion in Ovarian Cancer
Short Talk: Mapping Spatial Organization and Genetic Cell-State Regulators to Target Immune Evasion in Ovarian Cancer
Kyuson Yun, Houston Methodist/Weill Cornell Medical College
Short Talk: A Novel Functional Precision Oncology Platform Technology: E-Slice with Intact TME for Immunotherapy and Other Cancer Therapy Response Measurements from Human Tumors
Short Talk: A Novel Functional Precision Oncology Platform Technology: E-Slice with Intact TME for Immunotherapy and Other Cancer Therapy Response Measurements from Human Tumors
Social Hour with Lite Bites
7:00–8:00 PM
Peaks 1 - 3
Poster Session 2
7:30–10:00 PM
Peaks 1 - 3
Wednesday, January 15, 2025
Breakfast
7:00–8:00 AM
Peaks 1 - 3
Technologies for Biomarker Discovery (Discovery Through Application in the Clinic)
8:00–11:00 AM
Peaks 4 & 5
John D. Carpten, City of Hope Cancer Center
Assessing the Tumor and Immune Microenvironment Using Spatial Transcriptomics
Assessing the Tumor and Immune Microenvironment Using Spatial Transcriptomics
Christina Curtis, Stanford University
Integrating Systems Biology in Precision Oncology
Integrating Systems Biology in Precision Oncology
Colin D. Weekes, Massachusetts General Hospital
Harnessing Tumor Plasticity for Therapeutic Intent
Harnessing Tumor Plasticity for Therapeutic Intent
Ericca Stamper, Dovetail Genomics, Part of Cantata Bio LCC
Short Talk: Linkprep™ – A Comprehensive Assay for Cancer Genome Characterization that Enables Ultra-Sensitive Detection of Structural Variants
Short Talk: Linkprep™ – A Comprehensive Assay for Cancer Genome Characterization that Enables Ultra-Sensitive Detection of Structural Variants
Harmanpreet Singh †, Augusta University
Short Talk: Optical Genome Mapping as a Next Generation Tool for Molecular Profiling of Solid Tumors
Short Talk: Optical Genome Mapping as a Next Generation Tool for Molecular Profiling of Solid Tumors
Emily Madden, EpiCypher, Inc
Short Talk: Chromatin Profiling from Formalin-Fixed Paraffin-Embedded Samples for Biomarker Discovery
Short Talk: Chromatin Profiling from Formalin-Fixed Paraffin-Embedded Samples for Biomarker Discovery
Oliver Jonas, Brigham & Women's Hospital
Short Talk: Clinical Implementation of Implantable Microdevices to Identify Highly Effective Treatment Combinations in Cancer Patients
Short Talk: Clinical Implementation of Implantable Microdevices to Identify Highly Effective Treatment Combinations in Cancer Patients
Coffee Break
9:00–9:20 AM
Colorado Ballroom Foyer
On Own for Lunch
11:00–2:30 PM
Coffee Available
4:30–5:00 PM
Colorado Ballroom Foyer
Data Science, Informatics, AI & Machine Learning
5:00–6:45 PM
Peaks 4 & 5
David Craig, City of Hope
Informatics Strategies for Incorporating Genetic Ancestry in Precision Oncology
Informatics Strategies for Incorporating Genetic Ancestry in Precision Oncology
Benjamin Greenbaum, Memorial Sloan Kettering Cancer Center
Predicting Immunogenic Neoantigens in Cancer
Predicting Immunogenic Neoantigens in Cancer
Eliezer M. Van Allen, Dana-Farber Cancer Institute
Computational Approaches to Identify Mechanisms of Immunotherapy Response
Computational Approaches to Identify Mechanisms of Immunotherapy Response
John Paul Shen †, University of Texas MD Anderson
Short Talk: Clinical Implementation of Implantable Microdevices to Identify Highly Effective Treatment Combinations in Cancer Patients
Short Talk: Clinical Implementation of Implantable Microdevices to Identify Highly Effective Treatment Combinations in Cancer Patients
Meeting Wrap-Up: Outcomes and Future Directions (Organizers)
6:45–7:00 PM
Peaks 4 & 5
Social Hour with Lite Bites
7:00–8:00 PM
Peaks 1 - 3
Cash Bar
8:00–9:00 PM
Peaks 1 - 3
Entertainment
8:00–9:00 PM
Peaks 1 - 3
Thursday, January 16, 2025
Fundraising
Departure
12:00–11:59 PM
Subscribe for Updates